GGrantIndex
← Search

Gene Transfer

$369,893P30FY2014CANIH

Sloan-Kettering Inst Can Research, New York NY

Investigators

Linked publications, trials & patents

Trial NCT03699631Trial NCT02595918Trial NCT02417701Trial NCT02219737Trial NCT02152995Trial NCT01979523Trial NCT01947023Trial NCT01902160Trial NCT01705340Trial NCT01643278Trial NCT01638546Trial NCT01587352Trial NCT01585805Trial NCT01326702Trial NCT01281865Trial NCT01196416Trial NCT01154452Trial NCT01143402Trial NCT01119599Trial NCT01051557Trial NCT01026623Trial NCT01016015Trial NCT00957905Trial NCT00866177Trial NCT00729157Trial NCT00639509Trial NCT00601692Trial NCT00589472Trial NCT00570401Trial NCT00567229Trial NCT00550628Trial NCT00541034Trial NCT00528450Trial NCT00522301Trial NCT00521014Trial NCT00519974Trial NCT00514254Trial NCT00498927Trial NCT00483678Trial NCT00474994Trial NCT00471679Trial NCT00471601Trial NCT00470574Trial NCT00470470Trial NCT00462982Trial NCT00462501Trial NCT00459875Trial NCT00458705Trial NCT00453310Trial NCT00450827Trial NCT00416351Trial NCT00404365Trial NCT00398138Trial NCT00397904Trial NCT00369174Trial NCT00354679Trial NCT00334893Trial NCT00324480Trial NCT00245102Trial NCT00104845Trial NCT00090337Trial NCT00089245Trial NCT00087009Trial NCT00072345Trial NCT00072319Trial NCT00070057Trial NCT00067015Trial NCT00062374Trial NCT00059891Trial NCT00058253Trial NCT00054132Trial NCT00046917Trial NCT00040898Trial NCT00040872Trial NCT00039286Trial NCT00037011Trial NCT00036933Trial NCT00028730Trial NCT00024258Trial NCT00023764Trial NCT00020891Trial NCT00016146Trial NCT00014534Trial NCT00014469Trial NCT00008294Trial NCT00008242Trial NCT00006044Trial NCT00004245Trial NCT00004066Trial NCT00003923Trial NCT00003819Trial NCT00003173Trial NCT00003023Trial NCT00002981Trial NCT00002930Trial NCT00002766Trial NCT00002738Trial NCT00002718Trial NCT00002663Trial NCT00002558

Abstract

The Gene Transfer and Somatic Cell Engineering Core (GTF) supports the preclinical translation and clinical implementation of gene transfer studies at MSKCC. The projects supported are highly dependent on achieving efficient gene transfer in primary cells, including hematopoietic progenitor cells, T lymphocytes and dendritic cells. In the upcoming grant cycle, the GTF will focus on the implementation of Phase l/ll clinical trials and on the development and optimization of clinical cell engineering processes. The specific alms of the GTF are to carry out: 1) Expansion and transduction of patient cells for clinical trials utilizing expanded and/or genetically modified cells; 2) Generation and characterization of high-titer producer cell clones, master cell banks (MCB); 3) Production and titration of 5 to 15 liter batches of clinical viral stocks in semi-closed systems; 4) Biosafety testing in cultured packaging cell clones (MCB), viral stocks and clinical specimen; 5) Monitoring of retroviral vector copy number and integration sites by LAM-PCR in patient cells; and 6) Cell banking, storage of viral stocks, plasmid DNA and clinical specimens. In addition, the GTF provides essential advisory and training functions for generation of research grade reagents. The GTF is a repository for numerous reagents and protocols that are made available to investigators at MSKCC. The centralization of cell transdudion, vector production and plasmid DNA manufacturing in the GTF decreases the cost of clinical development. It also ensures high quality, consistency and timely implementation of molecular and cellular processes, and their availability to all investigators at the Center both at the preclinical and clinical stages. Over the last funding period the GTF enabled the successful implementation of 7 clinical trials currently open for enrollment under 4 investigational new drug applications. The services of the GTF supported the research of 11 investigators in the past year. During the past grant period the Core contributed to 107 publications of researchers from 3 programs.

View original record on NIH RePORTER →